Nls Pharmaceutics Ltd. - Understand $nlsp stock

$NLSP Market Cap: $6.7 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$22.06M

TTM

Current Assets

$1.192M

Q2 2024

Current Liabilities

$7.718M

Q2 2024

Current Ratio

15.45%

Q2 2024

Total Assets

$1.193M

Q2 2024

Total Liabilities

$10.46M

Q2 2024

Book Value

-$9.268M

Q2 2024

Cash

$552.8K

Q2 2024

P/E

-0.3037

Nov 29, 2024 EST

Free Cash Flow

-$8.602M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$5.899M	$6.506M	$5.941M	$2.200M	$2.490M	$2.010M	$1.440M
YoY Change	-9.33%	9.5%	170.05%	-11.65%	23.88%	39.58%
% of Gross Profit
Research & Development	$5.908M	$8.977M	$5.919M	$100.0K	$1.700M	$1.440M	$4.320M
YoY Change	-34.18%	51.65%	5819.45%	-94.12%	18.06%	-66.67%
% of Gross Profit
Depreciation & Amortization	$11.41K	$11.41K	$10.05K	$0.00
YoY Change	0.0%	13.51%
% of Gross Profit
Operating Expenses	$11.81M	$15.48M	$11.86M	$2.300M	$4.200M	$3.450M	$5.770M
YoY Change	-23.74%	30.54%	415.68%	-45.24%	21.74%	-40.21%
Operating Profit	-$11.80M	-$15.48M	-$11.86M	-$2.299M
YoY Change	-23.78%	30.54%	415.82%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$119.9K	-$90.82K	-$85.45K	-$560.0K	-$890.0K	-$1.070M	-$890.0K
YoY Change	-232.04%	6.28%	-84.74%	-37.08%	-16.82%	20.22%
% of Operating Profit
Other Income/Expense, Net	-$219.8K	$10.05K	-$17.32K	-$328.4K
YoY Change	-2288.27%	-157.99%	-94.72%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$12.17M	-$16.50M	-$11.95M	-$2.860M	-$5.450M	-$5.150M	-$6.660M
YoY Change	-26.21%	38.08%	317.7%	-47.52%	5.83%	-22.67%
Income Tax						$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.17M	-$16.50M	-$11.95M	-$2.860M	-$5.450M	-$5.150M	-$6.660M
YoY Change	-26.21%	38.08%	317.7%	-47.52%	5.83%	-22.67%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.32	-$0.84	-$1.00	-$0.41
Diluted Earnings Per Share	-$0.32	-$0.84	-$1.004M	-$242.8K	-$462.6K	-$437.2K	-$565.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$897.7K	$8.948M	$5.431M	$90.00K	$220.0K	$10.00K	$2.180M
YoY Change	-89.97%	64.76%	5934.67%	-59.09%	2100.0%	-99.54%
Cash & Equivalents	$897.7K	$8.948M	$5.431M	$90.00K	$220.0K	$10.00K	$2.180M
Short-Term Investments
Other Short-Term Assets	$890.3K	$256.8K	$253.4K	$40.00K	$110.0K	$50.00K	$70.00K
YoY Change	246.74%	1.33%	533.5%	-63.64%	120.0%	-28.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.823M	$9.246M	$5.723M	$200.0K	$380.0K	$90.00K	$2.270M
YoY Change	-80.28%	61.56%	2761.58%	-47.37%	322.22%	-96.04%
Property, Plant & Equipment	$6.690K	$18.10K	$29.51K
YoY Change	-63.04%	-38.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$16.89K	$12.14K	$12.04K	$950.0K	$260.0K
YoY Change	39.13%	0.83%	-98.73%	265.38%
Total Long-Term Assets	$23.58K	$30.24K	$41.55K	$1.010M	$320.0K	$60.00K	$20.00K
YoY Change	-22.02%	-27.22%	-95.89%	215.63%	433.33%	200.0%
Total Assets	$1.847M	$9.277M	$5.765M	$1.210M	$700.0K	$150.0K	$2.290M
YoY Change
Accounts Payable	$4.634M	$2.373M	$1.737M	$4.010M	$2.510M	$1.130M	$560.0K
YoY Change	95.24%	36.63%	-56.68%	59.76%	122.12%	101.79%
Accrued Expenses	$1.652M	$986.4K	$666.5K	$1.430M	$840.0K	$580.0K	$430.0K
YoY Change	67.5%	48.01%	-53.4%	70.24%	44.83%	34.88%
Deferred Revenue
YoY Change
Short-Term Debt	$1.634M	$0.00	$0.00	$1.160M	$540.0K	$560.0K	$0.00
YoY Change			-100.0%	114.81%	-3.57%
Long-Term Debt Due			$0.00	$610.0K	$150.0K	$150.0K	$0.00
YoY Change			-100.0%	306.67%	0.0%
Total Short-Term Liabilities	$7.920M	$3.360M	$2.403M	$7.200M	$4.040M	$2.410M	$990.0K
YoY Change	135.72%	39.79%	-66.62%	78.22%	67.63%	143.43%
Long-Term Debt	$0.00	$0.00	$0.00	$310.0K	$150.0K	$6.390M	$8.870M
YoY Change			-100.0%	106.67%	-97.65%	-27.96%
Other Long-Term Liabilities	$2.761M	$2.636M	$2.819M	$2.680M	$2.680M	$160.0K	$150.0K
YoY Change	4.73%	-6.48%	5.18%	0.0%	1575.0%	6.67%
Total Long-Term Liabilities	$2.761M	$2.636M	$2.819M	$2.990M	$2.830M	$6.550M	$9.020M
YoY Change	4.73%	-6.48%	-5.72%	5.65%	-56.79%	-27.38%
Total Liabilities	$10.68M	$5.996M	$5.222M	$10.20M	$6.870M	$8.960M	$10.01M
YoY Change	78.13%	14.81%	-48.8%	48.47%	-23.33%	-10.49%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	38.18M shares	19.68M shares	11.90M shares	6.960M shares
Diluted Shares Outstanding	38.18M shares	19.68M shares	11.90M shares	6.960M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $6.7003 Million

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics AG is a CH-based company operating in Pharmaceuticals industry. The company is headquartered in Zurich, Zuerich and currently employs 3 full-time employees. The company went IPO on 2021-01-29. NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.

Industry: Pharmaceutical Preparations Peers: Oculis Holding AG